BC PharmaCare Drug Information

The drug below is being considered for coverage under the BC PharmaCare program. PharmaCare is a government-funded drug plan that helps B.C. residents with the cost of eligible prescription drugs and medical supplies. For more information about PharmaCare, visit the PharmaCare website.

PharmaCare reviews each drug for treating a specific illness or medical condition (also called an "indication"). If PharmaCare decides to cover a drug, that coverage applies only to the indication(s) specified. In some cases, PharmaCare covers a drug only for people who have not responded to other drugs that treat the same indication.

More information about the PharmaCare drug review process is provided on the last page of this document.

Drug information	
Generic name (scientific name)	**fluticasone furoate, umeclidinium and vilanterol**
Brand name	**Trelegy Ellipta**
Manufacturer	GlaxoSmithKline Inc.
Indication	For the long-term, once-daily, maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a maintenance combination of a medium or high dose of an inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA).
Has the drug been reviewed by CDA-AMC, or will CDA-AMC be reviewing it? (See note below.)	Yes For more information about the CDA-AMC Reimbursement Review (CRR) of fluticasone furoate, umeclidinium and vilanterol (Trelegy Ellipta), Search the CDA-AMC Reports.
Public input start date	**Wednesday, October 28, 2026**
Public input closing date	**Tuesday, November 24, 2026, at 11:59 pm**
How is the drug taken?	Trelegy Ellipta is inhaled orally (by the mouth).
How often is the drug taken?	A single dose of Trelegy Ellipta is inhaled once daily at the same time of day each day.

Drug information	
General drug and/or drug study information	Trelegy Ellipta is being reviewed by the Ministry of Health for the long-term, once-daily, maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a maintenance combination of a medium or high dose of an inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA). Asthma is a chronic inflammatory disease of the airways in the lungs. In people with asthma, the airways become inflamed and narrowed and may produce excess mucus, which can limit airflow and make breathing difficult. Symptoms can vary over time and commonly include coughing, wheezing, shortness of breath, and chest tightness. Trelegy Ellipta contains three active ingredients that work in different ways to improve breathing. Fluticasone reduces inflammation in the airways. Umeclidinium blocks signals that cause the muscles around the airways to tighten, helping to keep the airways open. Vilanterol relaxes the muscles surrounding the airways, allowing them to widen and making it easier for air to move in and out of the lungs. Together, these effects can improve airflow and help control asthma symptoms. Trelegy Ellipta combines three different types of asthma medication into a single, once-daily inhaler. This may reduce the number of inhalers a person needs to use compared with taking these medicines separately.
Other considerations	None

Note:
CDA-AMC (Canada's Drug Agency-L'Agence des Médicaments du Canada) is a national organization that reviews drugs on behalf of Canadian public sector plans when drug manufacturers want those plans to provide coverage for the drug. For detailed information about the PharmaCare drug review process, including the role of the CDA-AMC Reimbursement Review (CRR) in that process, visit How PharmaCare Decides Which Drugs to Cover.

Table of Comparators Used to Treat the Same Indication		
Generic Name (Brand Name) of Drug Comparator	**Dosage Form**	**PharmaCare Status (if and how the drug is already covered)**
fluticasone furoate-umeclidinium-vilanterol (Trelegy Ellipta)	Dry Powder Inhaler (DPI)	Under Review for Asthma Limited Coverage for moderate to severe chronic obstructive pulmonary disease (COPD)
Single Inhaler Triple Therapy		
indacaterol-glycopyrronium-mometasone furoate (Enerzair Breezhaler)	DPI	Limited Coverage
Multiple Inhaler Triple Therapy (LAMA)		
tiotropium bromide (Spiriva Respimat)	Soft Mist Inhaler (SMI)	Regular Benefit
Single Inhaler Dual Therapy: inhaled corticosteroid-long-acting beta-agonist (ICS-LABA)		
fluticasone furoate-vilanterol (Breo Ellipta)	DPI	Limited Coverage
fluticasone propionate-salmeterol (Advair)	Metered-Dose Inhaler (MDI)	Limited Coverage
fluticasone propionate-salmeterol (Advair Diskus and generic)	DPI	Limited Coverage
budesonide-formoterol fumarate (Symbicort)	DPI	Limited Coverage
mometasone furoate-indacaterol acetate (Atectura Breezhaler)	Inhaled capsule	Limited Coverage
mometasone furoate-formoterol fumarate (Zenhale)	MDI	Limited Coverage

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent national organization called Canada's Drug Agency (CDA-AMC) provides evidence-based recommendations to public drug plans across Canada through its reimbursement review process.

As part of the CDA-AMC's Clinical Reimbursement Review process, the Canadian Drug Expert Committee (CDEC) makes reimbursement recommendations for non-oncology pharmaceuticals to the participating federal, provincial, and territorial publicly funded drug plans. In developing its recommendations, the CDEC considers:

- whether the drug is safe and effective
- what the drug costs and whether it is a good value to the citizens of B.C.
- ethical considerations related to covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by considering:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the CDA-AMC
- the recommendations and reimbursement conditions of the CDEC
- if a Ministry Initiated review, the advice of an independent expert group called the Drug Benefit Council (DBC)
- BC-specific patient input collected through the Your Voice website
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit BC PharmaCare and Drug reviews for more information.

This document provides information only.
It does not take the place of advice from a physician or other qualified health care provider.